Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1947 | Inhaled nitric oxide (iNO) Wiki | 0.71 |
| drug3484 | SNO Wiki | 0.71 |
| drug2743 | Oxygen gas Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
Description: As assessed per treating physician's discretion.
Measure: Incidence of treatment emergent adverse events Time: Up to 14 daysDescription: Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.
Measure: Incidence of adverse events Time: Up to 6 hoursDescription: Incidence of increase to > 5% total methemoglobin as assessed by pulse oximetry.
Measure: Incidence of methemoglobinemia Time: Up to 14 daysDescription: Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).
Measure: Number of participants with progression of respiratory failure Time: Up to 14 daysDescription: The number of days until hypoxemia is resolved as per treating physician assessment
Measure: Time until resolution of hypoxemia Time: Up to 14 daysDescription: Incidence of death during hospitalization and after discharge up to 28 days
Measure: Incidence of mortality Time: Up to 28 daysDescription: Number of days of hospitalization
Measure: Duration of hospitalization Time: Up to 28 daysThe primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Description: Total hospitalization days: Hospitalization data will be collected from the EMR on Day 30. Treatment will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
Measure: Length of Hospital Stay Time: 30 daysDescription: Total ventilator days:Ventilator Days will be recorded for each day through Day 30. The number of days on the ventilator will be counted and then used to calculate the number of ventilator free days. Days that subjects are weaning off and on the ventilator will be counted as days on the ventilator.
Measure: Number of Ventilator Days Time: 30 daysDescription: Total days in ICU: Intensive Care Unit Days will be recorded for each day through Day 30. Days will be counted in 24-hour periods, any partial days will be counted as a whole day. The level of ICU care needed will be recorded, based on clear definitions and specific clinical criteria in the covid-19 critical care procedure manual, as follows: Level 1 - Mechanical ventilation and intensivist support. Patient is stable on lung protective equipment. Level 2 - Advanced mechanical ventilation (capability to prone) and 24 hour intensivist support. Patient is hypoxic. Patient is stabilized on escalated ventilator settings (high PEEP, prone, etc.) Level 3 - Advanced oxygenation/ventilation strategies, including ECMO and 24 intensivist support. Patient is severely hypoxic (ARDS), code status is discussed, palliative consult is discussed, RESP-ECMO parameters, and patient is ECMO candidate.
Measure: Length of Intensive Care Time: 30 daysDescription: 30-day all-cause mortality
Measure: All-Cause Mortality Time: 30 daysDescription: Adverse events related to SNO therapy.
Measure: Treatment Emergent Adverse Events Time: 30 daysDescription: Number of days required to see a greater than 2 point improvement on a 7-point respiratory status assessment ordinal scale. 7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95% Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94% Supplemental nasal oxygen >2 and <= 5 liters/min Supplemental nasal oxygen >5 liters/min HFNC or NIV with FiO2 > 50% Intubation or ECMO Death
Measure: Time to Respiratory Status Improvement Time: 30 daysDescription: Proportion of patients in each stage at maximum severity on the 7-point clinical status assessment ordinal scale. Clinical status will be assessed using a 7-point ordinal scale as follows: Death Hospitalized, on invasive mechanical ventilation or ECMO Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring low flow supplemental oxygen Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Not hospitalized
Measure: Clinical Status Time: 30 daysDescription: Respiratory clinical status assessed by a 7-point respiratory status ordinal scale that captures oxygen requirement, ventilator support or death. 7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95% Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94% Supplemental nasal oxygen >2 and <= 5 liters/min Supplemental nasal oxygen >5 liters/min HFNC or NIV with FiO2 > 50% Intubation or ECMO Death
Measure: Respiratory Clinical Status Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports